Company News

Share this article:

Abbott opened a nutrition product manufacturing facility in Singapore, in order to meet increasing regional demand for its pediatric products, including Similac, according to company statement. The facility represents the company's largest nutrition investment to date, at $300 million. According to Abbott, the facility will serve up to one million Asian infants and children each year.

 

FDA halted the review of all NDA's received from a Ranbaxy Laboratories plant in India, after discovering falsified data. In a letter to Ranbaxy, CDER director Janet Woodcock said the findings “indicate a pattern and practice of submitting untrue statements of material fact and other wrongful conduct, which raise significant questions regarding the reliability of the data and information contained in applications (pending and approved) that [Ranbaxy] has filed with the agency and which contain data developed at the Ranbaxy Laboratories, Paonta Sahib site.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.